30% of Americans are living with some form of chronic or severe pain.
More people live with CHRONIC PAIN than CANCER, HEART DISEASE, and DIABETES, combined.
300% increase in opioid prescriptions in the last decade
1 in 4 patients become addicted to opioids
More than $560B spent annually on healthcare due to pain disorders
121 Americans die every day from an opioid overdose
We have developed an epigenetic gene therapy to target pain that is non-addictive, highly specific, and long-lasting.
We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by utilizing a novel gene therapy to target pain. In our proof of concept, we have demonstrated our epigenetic therapy increases pain tolerance and lowers pain levels.
Founded in 2018, Navega Therapeutics Inc. is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. Our gene therapy platform has the advantage of being highly specific and long-lasting, which has not been achieved by small molecules thus far. Our pipeline includes different types of pain to improve the quality of life of millions of patients.